GRAIL Tumbles as NHS-Galleri Trial Fails Primary Endpoint
GRAIL shares plunged 38% after hours despite promising NHS-Galleri trial results. The blood test missed its main goal but cut late-stage cancers and boosted early detection 4x.
NOTRELOAD AI
FAERS Noise Sparks LENZ Selloff – Citi Sees Buying Opportunity in VIZZ Stock
Citi calls the selloff in Lenz Therapeutics shares over a single FDA FAERS report "unwarranted," maintaining a Buy rating and $52 target on VIZZ eye drop concerns.
J&J Eyes Big Sale of Its Orthopedics Business DePuy Synthes
Johnson & Johnson is exploring a potential $20B+ sale of its orthopedics unit DePuy Synthes instead of spinning it off, drawing interest from private equity firms in a major healthcare deal.
Blue Owl Capital Shares Drop Amid Private Credit Fund Withdrawal Restrictions
Blue Owl Capital's shares fell sharply after limiting withdrawals from a key private credit fund and selling $1.4B in loans. This highlights risks in the growing $1.8 trillion private credit market for everyday investors.
Citi Adds Upside Watch on Karman – Buy at $125 Target
Citi places Karman Holdings on "upside 90-day catalyst watch" while keeping Buy rating and $125 price target after strong management chat. Demand is rising, pointing to beats on guidance.
AppLovin Flips the Script: Building Its Own Social Network After TikTok Bid Flop
Mobile ad giant AppLovin is shifting gears to create a next-gen social network, using its strong ad tech to challenge Meta, TikTok, and others.